NVDA+2.54%AAPL+1.32%GOOGL−1.62%MSFT+0.20%AMZN−0.10%TSM+1.60%SPCX+7.79%META+0.47%
StockVS

NASDAQ · Biotechnology · USD

ImmunityBio, Inc. (IBRX) Stock Analysis

ImmunityBio, Inc. (IBRX) is a Biotechnology stock listed on NASDAQ and quoted in US Dollar.

Last Updated: October 21, 2026

IBRX

$8.64

−$0.13 (−1.48%)

Oct 21, 2026 · Market close

Compare

Price History

Hover for the daily close. The dotted line marks the period open.

Compare IBRX with… →

IBRX Key Statistics

As of Oct 21, 2026
Trading
Open
$8.88
Previous Close
$8.77
Day's Range
8.32–8.99
52-Week Range
1.95–12.43
Volume
11.46M
BetaHow much the share price moves relative to the wider market. 1.0 moves in line with it; above 1.0 swings more, below 1.0 less.
0.03
Valuation
Market Cap
$9.16B
P/E Ratio
unprofitable
P/S ratioMarket value divided by annual revenue. Useful for companies that are not yet profitable, where a P/E cannot be calculated.
55.23
EPS (ttm)Profit attributable to each share over the last twelve months.
−0.97
Financials (FY)
Revenue (FY)
$113.29M+668.31%
Net Income (FY)
−$351.40M
Shares OutstandingThe total number of shares held by all investors. Market value is this figure multiplied by the share price.
1.06B
1-Year Return
+254.10%
Dividend and dates
Earnings Date
November 3, 2026estimated
Avg Volume
11.48M

Only metrics the company reports are shown. Data provided by Yahoo Finance via yfinance. Updated daily.

Key facts

As of October 21, 2026, IBRX closed at $8.64, +254.10% over 1 year.

ImmunityBio, Inc. (IBRX) has a market capitalization of $9.16B.

In fiscal 2025, IBRX reported revenue of $113.29M.

IBRX Stock Return by Calendar Year

ImmunityBio, Inc. (IBRX) 10-year return: what $10,000 became

1 year
$10,000 $35,410
+254.10%
5 years
$10,000 $10,225
+2.25%
10 years
$10,000 $13,032
+30.32%

If you had invested $10,000 in ImmunityBio, Inc. (IBRX) 10 years ago, at the close on October 21, 2016, it would have been worth $13,032 at the close on October 21, 2026: +30.32% in total, +2.68% a year. A historical calculation from closing prices adjusted for splits and dividends, before fees and taxes.

Calendar-year returns computed from daily closing prices. Partial years are shown muted and marked with an asterisk.

YearReturn
2026 (partial year)+336.36%
2025−22.66%
2024−49.00%
2023−0.99%
2022−16.61%
2021−54.39%
2020+251.72%
2019+226.72%
2018−74.16%
2017−21.50%
2016 (partial year)−22.49%

As of October 21, 2026.

IBRX Revenue and Earnings by Fiscal Year

FY ends December
Fiscal yearRevenueNet incomeNet margin
2025$113.29M−$351.40M−310.2%
2024$14.75M−$413.56M−2,804.8%
2023$622.00K−$583.20M−93,761.4%
2022$240.00K−$416.57M−173,569.6%
Fiscal yearRevenueGross profitOperating incomeNet incomeNet margin
2025$113.29M$112.54M−$256.03M−$351.40M−310.2%
2024$14.75M$14.75M−$344.18M−$413.56M−2,804.8%
2023$622.00K$622.00K−$361.36M−$583.20M−93,761.4%
2022$240.00K$240.00K−$350.62M−$416.57M−173,569.6%

Annual figures as reported, in the company's reporting currency. As of December 31, 2025.

IBRX Valuation vs Biotechnology Median

Median of 608 stocks
MetricIBRXBiotechnology medianvs median
P/S ratio55.2313.304.2x the median

Medians across 608 Biotechnology stocks that report the metric. Medians, not averages, so one outlier cannot move them. As of October 21, 2026.

Recent News

All 20 articles ↓

News provided by third-party sources. Not financial advice.

Analysis

Data-derived

Company Overview

ImmunityBio, Inc. (IBRX) carries a market capitalisation of $9.16B. The company sits in the Healthcare sector, in the Biotechnology industry. Headcount on file is 684.

The 52-week range on file runs from $1.95 to $12.43. IBRX last closed at $8.64 on October 21, 2026. That is −$0.13 (−1.48%) against the previous close. The latest close sits 343.08% above that 52-week low.

Financial Health

Fiscal 2025 revenue came to $113.29M. Against the prior fiscal year total of $14.75M, that is a change of +668.31%. The same year closed with a net loss of $351.40M. Trailing earnings per share are −0.97.

Across the 4 fiscal years on file, revenue moves from $240.00K in 2022 to $113.29M in 2025. Of those 4 years, 0 report positive net income.

Valuation Assessment

The record shows negative trailing earnings, so no price-to-earnings ratio is published. The price-to-sales ratio is 55.23. On price-to-sales that is 4.2 times the Biotechnology median of 13.3. The medians here are taken across 608 Biotechnology companies that report the metric.

The trailing one-year total return is +254.10%. Across 10 years the annualized return works out at +2.68%. Beta against the wider market is reported at 0.03. Daily returns over the trailing 10 years annualize to a volatility of 111.4%.

Growth & Income

The record shows no dividend for IBRX.

So far in 2026 the total return is +336.36%. Across the complete calendar years on file, 2020 returned +251.72% and 2018 returned −74.16%. Of the 9 complete calendar years on file, 2 finished higher.

Peer Comparison

ImmunityBio, Inc. (IBRX) operates in the Biotechnology industry. Here is how it compares to its closest peers by market capitalization:

Company Ticker Market Cap P/E Ratio
ImmunityBio, Inc. IBRX $9.16B —
Vertex Pharmaceuticals Incorporated VRTX $132.95B 30.4
Moderna, Inc. MRNA $98.14B —
Regeneron Pharmaceuticals, Inc. REGN $82.95B 19.9

The Biotechnology industry average P/E ratio is 16.6x. ImmunityBio, Inc. has no P/E ratio because it is not currently profitable.

Every figure above is read from this page's own data on each daily rebuild. Informational only, not financial advice. As of October 21, 2026.

Related Biotechnology Stocks

VRTX

Vertex Pharmaceuticals Incorporated

$132.95B

 MRNA

Moderna, Inc.

$98.14B

 REGN

Regeneron Pharmaceuticals, Inc.

$82.95B

 ARGX

argenx SE

$55.97B

 ONC

BeOne Medicines AG

$43.97B

 RVMD

Revolution Medicines, Inc.

$41.64B
View all Biotechnology stocks →

Popular Healthcare Stocks

LLY

Eli Lilly and Company

$1.13T

 JNJ

Johnson & Johnson

$621.22B

 ABBV

AbbVie Inc.

$503.27B

 UNH

UnitedHealth Group Incorporated

$374.30B

 MRK

Merck & Co., Inc.

$369.78B
View all Healthcare stocks →

About ImmunityBio, Inc.

ImmunityBio, Inc., a biotechnology company, focuses on innovating, developing, and commercializing next-generation immunotherapies designed to activate the patient's immune system and deliver durable protection against cancer and infectious diseases. Its platforms for the development of biologic products and product candidates that include cytokine fusion proteins, DNA and vaccine vectors, and cell therapies. The company's platform has generated first-in-human therapeutic agents that are planned to be studied in clinical trials in liquid and solid tumors. Its lead biologic product candidate includes Anktiva, an FDA-approved immunotherapy in combination with bacillus calmette-guérin (BCG) for the treatment of adult patients with BCG unresponsive non-muscle invasive bladder cancer with carcinoma in situ, with or without papillary tumors; and 3M-052, a synthetic TLR7/8 agonist and 3M-052 formulations and related technology. The company has collaboration agreements with National Cancer Institute; Serum Institute of India Private Limited; and BeOne Medicines Ltd. It has license agreement with 3M Innovative Properties Company and Access to Advanced Health Institute. ImmunityBio, Inc. is based in San Diego, California.

Visit website →